?
Læs mere om arbejdspladslogin her.

Content area

Videnskab / 4. dec 2017

Immunterapi med checkpointhæmmere og endokrinologiske bivirkninger

Statusartikel
Dato
4. dec 2017
Forfattere
Line Bisgaard Jørgensen1, Lars Bastholt2 & Knud Yderstræde1 1) Endokrinologisk Afdeling, Odense Universitetshospital 2) Onkologisk Afdeling, Odense Universitets-hospital Ugeskr Læger 2017;179:V05170362
💬 0
Reference: 
Ugeskr Læger 2017;179:V05170362
Blad nummer: 
Sidetal: 
2-6
Immune checkpoint inhibitors and endocrinological side effects
Immune checkpoint inhibitors including anti-cytotoxic T-lymphocyte-associated antigen-4 and anti-programmed cell death-1 have revolutionized cancer therapy but have also induced serious immune-related adverse events including hormonal dysfunction. The objective of this review is to characterize the incidence, clinical presentation, management and prognosis of the endocrine-related adverse events including hypophysitis, thyroid dysfunction and diabetes mellitus. Combination therapy is associated with an increased risk of adverse events. We recommend close monitoring of the hormone levels and glycaemic status during and a year after treatment.

💬 0 Kommentarer

Du skal være logget ind for at læse denne artikel
Log ind

Du kan også købe adgang

Køb abonnement til Ugeskriftet.dk (der er forskellige abonnementstyper )

Right side

Nr. 4/2018

Senest kommenteret

Billeddiagnostisk udredning ved mistanke om akut lungeemboli
💬
1
Jens Aamann Andersen 19. feb 2018 17:27
Anklagemyndighed anker ikke OUH-sag
💬
1
Kristian Rørbæk Madsen 19. feb 2018 13:27
Lægerne bliver hørt
💬
1
Kristian Rørbæk Madsen 19. feb 2018 12:30